Sonoma Pharmaceuticals (SNOA) Deferred Taxes (2022 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Deferred Taxes came in at $431000.0 in Q1 2026, up 329.26% year-on-year from $100406.4 in Q1 2025, and up 563.44% quarter-over-quarter from -$93000.0 in Q2 2025.
Sonoma Pharmaceuticals (SNOA) Deferred Taxes (2022 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Deferred Taxes history runs 5 years deep, the most recent figure standing at $431000.0 for Q1 2026.
- On a quarterly basis, Deferred Taxes rose 329.26% year-over-year to $431000.0 in Q1 2026; TTM through Mar 2026 was $169000.0, a 147.34% increase from a year earlier, with the FY2026 full-year figure at $231000.0, up 164.71% from the prior year.
- Deferred Taxes advanced to $431000.0 in Q1 2026 per SNOA's latest filing, from -$93000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $829000.0 in Q1 2022 and bottomed at -$188000.0 in Q1 2025.
- The 5-year median for Deferred Taxes is -$54000.0 (2023), against an average of $63733.3.
- Across the five-year window, Deferred Taxes sank 193.53% in 2025 and surged 329.26% in 2026, its largest moves.
- Year by year, Deferred Taxes stood at -$105000.0 in 2022, then surged by 149.52% to $52000.0 in 2023, then slumped by 63.46% to $19000.0 in 2024, then sank by 589.47% to -$93000.0 in 2025, then surged by 563.44% to $431000.0 in 2026.
- Per Business Quant, the three latest SNOA Deferred Taxes figures stand at $431000.0 (Q1 2026), -$93000.0 (Q2 2025), and -$188000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -22.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 34.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 25.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -69.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -61.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | 431,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 431,000.00 |
| Jun 30, 2025 | -93,000.00 |
| Mar 31, 2025 | -188,000.00 |
| Dec 31, 2024 | 19,000.00 |
| Sep 30, 2024 | -66,000.00 |
| Jun 30, 2024 | -122,000.00 |
| Mar 31, 2024 | 201,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | -54,000.00 |
| Jun 30, 2023 | -90,000.00 |
| Mar 31, 2023 | 281,000.00 |
| Dec 31, 2022 | -105,000.00 |
| Sep 30, 2022 | -99,000.00 |
| Jun 30, 2022 | -40,000.00 |
| Mar 31, 2022 | 829,000.00 |